These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10907968)

  • 21. Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter.
    Banchs JE; Wolbrette DL; Samii SM; Penny-Peterson ED; Patel PP; Young SK; Gonzalez MD; Naccarelli GV
    J Interv Card Electrophysiol; 2008 Nov; 23(2):111-5. PubMed ID: 18688699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm.
    Tsikouris JP; Cox CD
    Pharmacotherapy; 2001 Dec; 21(12):1514-29. PubMed ID: 11765303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies.
    Jaiswal A; Goldbarg S
    Indian Heart J; 2014; 66(6):640-8. PubMed ID: 25634399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dofetilide: Electrophysiologic Effect, Efficacy, and Safety in Patients with Cardiac Arrhythmias.
    Shenasa F; Shenasa M
    Card Electrophysiol Clin; 2016 Jun; 8(2):423-36. PubMed ID: 27261832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study.
    Singh SN
    Card Electrophysiol Rev; 2003 Sep; 7(3):225-8. PubMed ID: 14739718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency of toxicity with chemical conversion of atrial fibrillation with dofetilide.
    Brumberg G; Gera N; Pray C; Adelstein E; Barrington W; Bazaz R; Mendenhall GS; Nemec J; Voigt A; Wang NC; Schwartzman D; Saba S; Jain SK
    Am J Cardiol; 2013 Aug; 112(4):505-8. PubMed ID: 23706388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase IV trial evaluating the effectiveness and safety of dofetilide.
    Guanzon AV; Crouch MA
    Ann Pharmacother; 2004; 38(7-8):1142-7. PubMed ID: 15161945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ibutilide: a new class III antiarrhythmic agent.
    Cropp JS; Antal EG; Talbert RL
    Pharmacotherapy; 1997; 17(1):1-9. PubMed ID: 9017761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation.
    Agusala K; Oesterle A; Kulkarni C; Caprio T; Subacius H; Passman R
    Pacing Clin Electrophysiol; 2015 Apr; 38(4):490-8. PubMed ID: 25626340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dofetilide versus quinidine for atrial flutter: viva la difference!?
    Olshansky B
    J Cardiovasc Electrophysiol; 1996 Sep; 7(9):828-32. PubMed ID: 8884511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation.
    Liu G; Xue X; Gao C; Huang J; Qi D; Zhang Y; Dong JZ; Ma CS; Yan GX
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28522677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New advances in class III antiarrhythmic drug therapy.
    Sager PT
    Curr Opin Cardiol; 1999 Jan; 14(1):15-23. PubMed ID: 9932203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter.
    Howard PA
    Ann Pharmacother; 1999 Jan; 33(1):38-47. PubMed ID: 9972384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Quarter of a Century Later: What is Dofetilide's Clinical Role Today?
    Wolbrette DL; Hussain S; Maraj I; Naccarelli GV
    J Cardiovasc Pharmacol Ther; 2019 Jan; 24(1):3-10. PubMed ID: 29940780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiarrhythmic effect of the Ca
    Kirchhoff JE; Diness JG; Abildgaard L; Sheykhzade M; Grunnet M; Jespersen T
    Pflugers Arch; 2016 Nov; 468(11-12):1853-1863. PubMed ID: 27722784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group.
    Frost L; Mortensen PE; Tingleff J; Platou ES; Christiansen EH; Christiansen N
    Int J Cardiol; 1997 Jan; 58(2):135-40. PubMed ID: 9049678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential effects of dofetilide, amiodarone, and class lc drugs on left and right atrial refractoriness and left atrial vulnerability in pigs.
    Wirth KJ; Knobloch K
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Feb; 363(2):166-74. PubMed ID: 11218069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A benefit-risk assessment of class III antiarrhythmic agents.
    Elming H; Brendorp B; Pehrson S; Pedersen OD; Køber L; Torp-Petersen C
    Expert Opin Drug Saf; 2004 Nov; 3(6):559-77. PubMed ID: 15500415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-exome sequencing reveals microsatellite DNA markers for response to dofetilide initiation in patients with persistent atrial fibrillation: A pilot study.
    Kinney N; Larsen TR; Kim DM; Varghese RT; Poelzing S; Garner HR; AlMahameed ST
    Clin Cardiol; 2018 Jun; 41(6):849-854. PubMed ID: 29671888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug.
    Crijns HJ; Van Gelder IC; Kingma JH; Dunselman PH; Gosselink AT; Lie KI
    Eur Heart J; 1994 Oct; 15(10):1403-8. PubMed ID: 7821320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.